[go: up one dir, main page]

DK1817079T3 - Behandling af inflammationer - Google Patents

Behandling af inflammationer

Info

Publication number
DK1817079T3
DK1817079T3 DK05813139T DK05813139T DK1817079T3 DK 1817079 T3 DK1817079 T3 DK 1817079T3 DK 05813139 T DK05813139 T DK 05813139T DK 05813139 T DK05813139 T DK 05813139T DK 1817079 T3 DK1817079 T3 DK 1817079T3
Authority
DK
Denmark
Prior art keywords
a3ar
inflammatory state
subject
level
wbc
Prior art date
Application number
DK05813139T
Other languages
Danish (da)
English (en)
Inventor
Pnina Fishman
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1817079(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of DK1817079T3 publication Critical patent/DK1817079T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK05813139T 2004-12-02 2005-11-30 Behandling af inflammationer DK1817079T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63219804P 2004-12-02 2004-12-02
US65771805P 2005-03-03 2005-03-03
PCT/IL2005/001280 WO2006059328A1 (fr) 2004-12-02 2005-11-30 Traitement anti-inflammatoire

Publications (1)

Publication Number Publication Date
DK1817079T3 true DK1817079T3 (da) 2008-11-17

Family

ID=35708899

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05813139T DK1817079T3 (da) 2004-12-02 2005-11-30 Behandling af inflammationer

Country Status (13)

Country Link
US (3) US20080056992A1 (fr)
EP (2) EP1817079B1 (fr)
JP (2) JP2008521883A (fr)
KR (2) KR20070090222A (fr)
AT (2) ATE434762T1 (fr)
AU (2) AU2005310873B2 (fr)
BR (2) BRPI0518795A2 (fr)
CA (2) CA2586773C (fr)
DE (2) DE602005008639D1 (fr)
DK (1) DK1817079T3 (fr)
ES (2) ES2309817T3 (fr)
MX (2) MX2007006501A (fr)
WO (2) WO2006059327A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043054A1 (fr) * 2005-10-12 2007-04-19 Can-Fite Biopharma Ltd. Traitement et suivi de l'etat pathologique du cancer du foie
US20080300213A1 (en) * 2005-11-30 2008-12-04 Pnina Fishman Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment
US20080183101A1 (en) * 2006-08-17 2008-07-31 Jonathan Richard Stonehouse Salivary analysis
WO2008023362A2 (fr) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Traitement du cancer
WO2008056361A1 (fr) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. Marqueur biologique du psoriasis
CN101646685B (zh) 2007-03-14 2014-12-17 坎-菲特生物药物有限公司 合成ib-meca的方法
IL200753A (en) 2009-09-06 2015-06-30 Can Fite Biopharma Ltd Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
CA2790869A1 (fr) * 2010-03-03 2011-09-09 Government Of The Usa, Represented By The Secretary, Department Of Healt H And Human Services Agonistes a3ar dans le cadre du traitement de l'uveite
WO2011158904A1 (fr) 2010-06-18 2011-12-22 株式会社林原生物化学研究所 Agent thérapeutique pour des maladies inflammatoires contenant de l'adénosine n1-oxyde en tant que principe actif
KR102095284B1 (ko) 2017-05-11 2020-04-01 (주)케어젠 메토트렉세이트와 펩타이드의 결합체

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181351A4 (fr) 1984-05-09 1989-06-21 Univ Australian Procede de modulation de la reaction immunitaire.
AU5182500A (en) 1996-08-01 2000-10-26 Kennedy Institute Of Rheumatology, The Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
DK0942740T3 (da) 1996-12-06 2003-12-15 Amgen Inc Kombinationsterapi under anvendelse af et TFN-bindende protein til behandling af TFN-medierede sygdomme
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
JP2004135657A (ja) * 2002-08-21 2004-05-13 Kyowa Hakko Kogyo Co Ltd ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物
US20040229246A1 (en) * 2002-10-21 2004-11-18 Can-Fite Biopharam Ltd. Diagnostic markers for therapeutic treatment
AU2003274649A1 (en) * 2002-10-21 2004-05-04 Can-Fite Biopharma Ltd. Diagnostic markers for therapeutic treatment
DE60315863T2 (de) * 2002-10-22 2008-05-15 Can-Fite Biopharma Ltd. A3ar als ein marker für einen erkrankungszustand
AU2003282359A1 (en) * 2002-11-19 2004-06-15 Can-Fite Biopharma Ltd. A3ar agonists for the treatment of inflammatory arthritis
WO2004086034A2 (fr) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees au recepteur adenosine a3 couple a la proteine g (adora3)
WO2005000246A2 (fr) 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methodes et compositions de traitement de polyarthrite rhumatoide
ATE363907T1 (de) 2003-12-29 2007-06-15 Can Fite Biopharma Ltd Verfahren zur behandlung von multipler sklerose

Also Published As

Publication number Publication date
CA2586773C (fr) 2018-03-27
CA2586773A1 (fr) 2006-06-08
US20100256084A1 (en) 2010-10-07
AU2005310874B2 (en) 2008-11-27
BRPI0518777A2 (pt) 2008-12-09
JP4842964B2 (ja) 2011-12-21
DE602005015135D1 (de) 2009-08-06
CA2586774A1 (fr) 2006-06-08
AU2005310873A1 (en) 2006-06-08
MX2007006500A (es) 2007-07-13
ES2327435T3 (es) 2009-10-29
ATE402739T1 (de) 2008-08-15
JP2008521883A (ja) 2008-06-26
JP2008522182A (ja) 2008-06-26
US8541182B2 (en) 2013-09-24
ATE434762T1 (de) 2009-07-15
ES2309817T3 (es) 2008-12-16
BRPI0518795A2 (pt) 2008-12-09
AU2005310873B2 (en) 2008-11-27
WO2006059327A1 (fr) 2006-06-08
WO2006059328A1 (fr) 2006-06-08
EP1817589B1 (fr) 2009-06-24
KR20070090222A (ko) 2007-09-05
EP1817079B1 (fr) 2008-07-30
US20080056992A1 (en) 2008-03-06
EP1817079A1 (fr) 2007-08-15
KR20070100261A (ko) 2007-10-10
MX2007006501A (es) 2007-07-13
US20130345163A1 (en) 2013-12-26
AU2005310874A1 (en) 2006-06-08
EP1817589A1 (fr) 2007-08-15
DE602005008639D1 (de) 2008-09-11

Similar Documents

Publication Publication Date Title
Błogowski et al. Clinical analysis of perioperative complement activity during ischemia/reperfusion injury following renal transplantation
EA201201199A1 (ru) Антагонисты активин-actrii и их применения для повышения уровней эритроцитов
DK2848938T3 (da) Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
WO2007123976A3 (fr) Établissement de profils d'anticorps pour la détermination de la sensibilité des patients à un traitement
DK1817079T3 (da) Behandling af inflammationer
ATE548050T1 (de) Diagnoseverfahren
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
EA200870410A1 (ru) Антагонисты киназы
BR112012031166A2 (pt) compensação baseada eminclinação incluindo sinais de saída secundários
MX2009008563A (es) Tratamiento de padecimientos inflamatorios utilizando celulas madre placentarias.
IT1394617B1 (it) Metodi integrati per la determinazione della corrosivita', dell'invecchiamento, del fingerprint, nonchè la diagnosi, la decontaminazione, la depolarizzazione e la detossificazione di oli
WO2010025393A3 (fr) Marqueurs biologiques protéiques et méthodes pour diagnostiquer la maladie de kawasaki
BR112012025517A2 (pt) ____________________________________________________________ anticorpo que reconhece fator inibidor de leucemia (lif) humano e uso de anti-lif anticorpos no tratamento de doenças associadas a proliferação celular não desejada
BRPI0819018A2 (pt) "métodos para determinar se um paciente possui risco aumentado de desenvolver hipertensão, para determinar se um paciente possui maior probalidade de se beneficiar do tratamento com um antagonista de vegf e kits para determinar se um paciente possui risco aumentado de desenvolver hipertensão e para determinar se um paciente possui maior probabilidade de se beneficiar do tratamento com um antagonista de vegf"
EP2300599A4 (fr) Augmentation de l'efficacité de la thérapie cellulaire comprenant le traitement avec l'alpha(1,3)fucosyltransférase
EP1828284A4 (fr) Copolymere bloc sulfone et membrane pour electrolyte l'utilisant
EA200802381A1 (ru) Лечение желудочно-кишечных расстройств антагонистами cgrp-пептида
DE602005023725D1 (de) Diagnose und überwachung von entzündlichen krankheiten mittels messung der zusätzlichen komponenten von leukozyten
DK2068938T3 (da) Optimering af behandlingen af Philadelphia-positiv leukæmi med ABL-tyrosinkinaseinhibitor imatinib
EP1718768A4 (fr) Procedes et compositions pour la determination de phenotype a tolerance vis-a-vis du greffon chez un sujet
MX2023001937A (es) Anticuerpos monoclonales, composiciones y métodos para detectar el factor d del complemento.
Weger et al. The methylenetetrahydrofolate reductase 677C> T gene polymorphism is not associated with chronic plaque psoriasis
WO2007044622A8 (fr) Utilisation de mif et d'agonistes de la voie mif
FR2900936B1 (fr) Procede et methodes de detection de la maladie d'alzheimer
WO2008039445A3 (fr) Polymorphismes du gène xbp-1 humain associés à une maladie intestinale inflammatoire